Exane Asset Management’s Biogen BIIB Stock Holding History

Exane Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,000	Closed	-$969K	–	30
2024 Q3	$969K	Buy	+5,000	New	+$1.05M	0.78%	15
2018 Q3	–	Sell	-40,708	Closed	-$11.8M	–	131
2018 Q2	$11.8M	Buy	40,708 +2,363	+6%	+$664K	5.11%	5
2018 Q1	$10.5M	Sell	38,345 -38,051	-50%	-$11.8M	3.15%	12
2017 Q4	$24.3M	Buy	76,396 +1,448	+2%	+$465K	7.56%	3
2017 Q3	$23.5M	Buy	74,948 +8,826	+13%	+$2.61M	4.59%	10
2017 Q2	$17.9M	Buy	+66,122	New	+$17.5M	5.6%	9
2016 Q4	–	Sell	-8,500	Closed	-$2.66M	–	37
2016 Q3	$2.66M	Buy	+8,500	New	+$2.52M	0.83%	28
2016 Q2	–	Sell	-73	Closed	-$19K	–	33
2016 Q1	$19K	Buy	+73	New	+$19.3K	0.01%	23

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Exane Asset Management's BIIB Position: Q4 2024 in Review

Exane Asset Management sold out of Biogen (BIIB) in Q4 2024, closing a stake of 5,000 shares — an estimated $969K sold.

Exane Asset Management first reported a position in BIIB in Q1 2016 and held it in 8 quarters. The position peaked at $24.3M in Q4 2017. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

Exane Asset Management reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
Exane Asset Management sold 5,000 Biogen shares in Q4 2024, an estimated $969K.
Exane Asset Management first reported a position in Biogen in Q1 2016 and held it in 8 quarters.
Exane Asset Management's Biogen position peaked at $24.3M in Q4 2017.
876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on Exane Asset Management's 13F filing for Q4 2024, filed 28 Jan 2025.